Dose Escalation Completed in Ph 1 Trial of INB-100; Enrollment for the Ph 2 Trial of INB-400 in 1L GBM initiated October 18, 2023
US FDA places lacutamab IND on partial clinical hold for new patient enrollment following one unexpected severe adverse reaction October 11, 2023
EXKIVITY® (mobocertinib) to be voluntary withdrawn from the U.S. for adult patients with EGFR Exon20 insertion+ mNSCLC whose disease has progressed on or after platinum-based chemotherapy October 11, 2023
First Subjects dosed in Ph 2 Portion of Trial Evaluating Annamycin + Cytarabine (Ara-C) for the Treatment of AML October 11, 2023
First Patient dosed in Landmark STAR-LLD Lenalidomide Ph 1b Trial in Multiple Myeloma October 11, 2023
Enrollment of 120 Patients for Ph 3 Trial of Denifanstat + Bevacizumab for Treatment of Recurrent GBM completed October 3, 2023
Ph 3 ENHANCE-2 study of magrolimab in patients with AML with TP53 mutations discontinued October 3, 2023
Ph 1/2 Study of Azeliragon in Patients Refractory to 1L Treatment of Metastatic Pancreatic Cancer initiated October 3, 2023
Ph 2 Study of Masofaniten (EPI-7386) + Enzalutamide in Patients with Metastatic CRPC initiated September 26, 2023
First Patient Dosed in Ph 1/2a Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer September 26, 2023
First Patient dosed in Ph 1/2 Trial of IMPT-314 for the Treatment of Aggressive B-cell Lymphoma September 26, 2023
First Patient in Ph 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ September 26, 2023
Patient Dosing with MT-302 initiated in Ph 1 Study for Advanced or Metastatic Epithelial Tumors September 19, 2023
First participant of cohort 3 in theranostic SECuRE trial of 64Cu/67Cu SAR-bisPSMA in metastatic CRPC treated at the highest dose level of 12GBq September 1, 2023
First participant of cohort 4 of the theranostic CL04 trial investigating 64Cu/67Cu SARTATE in neuroblastoma treated September 1, 2023
Two programmes evaluating CD47-blocking fusion protein evorpacept for patients with haematologic malignancies discontinued August 23, 2023
Enrollment opens for Keytruda® Arm in Ongoing Breast Cancer alpha-lactalbumin and AMHR2-ED-targeting Vaccine Clinical Trial August 16, 2023
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With NSCLC Harboring EGFR Exon 20 Insertion Mutations August 9, 2023
